Open AccessEFFICIENCY OF ANTI-INFLAMMATORY AND IMMUNOMODULATORY THERAPY OF COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN WITH RECURRENT RESPIRATORY DISEASES
Author(s) -
Т. Г. Маланичева,
Е. В. Агафонова,
С. С. Можгина
Publication year - 2018
Publication title -
rossijskij vestnik perinatologii i pediatrii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.139
H-Index - 4
eISSN - 2500-2228
pISSN - 1027-4065
DOI - 10.21508/1027-4065-2018-63-5-147-151
Subject(s) - medicine , pneumonia , respiratory system , community acquired pneumonia , tumor necrosis factor alpha , immune system , immunology , gastroenterology
Objective: to improve the methods of treatment of community-acquired pneumonia in children with recurrent respiratory diseases, taking into account the state of mucosal immunity. The authors examined 65 children from 3 to 7 years with community-acquired pneumonia and recurrent respiratory diseases. The main group consisted of 25 children receiving Fenspiride (4 mg / kg for 7 days) and immunomodulator Azoximer bromide (sublingually, 6 mg tablets twice a day for 10 days) in the complex anti-inflammatory therapy. The comparison group included 20 children receiving only Fenspiride (4 mg / kg for 7 days) as part of complex therapy. Control group included 20 children receiving only traditional therapy. We determined the levels of pro-inflammatory (IL-8, IL-1, α-factor tumor necrosis) and regulatory cytokines (IL-10 and γ-interferon) in induced expectoration by an immune enzyme analysis. We found that due to the therapy the imbalance of both pro-inflammatory and regulatory cytokines was leveled in the main group against a background of positive clinical efficacy that is manifested by reduction of the febrile period, faster relief of respiratory syndrome and local pulmonary changes, and 2 times reduction in the frequency of recurrent respiratory diseases.